3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
29
Neoplasms
5
Glioma
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Melanoma
3
Glioblastoma
3
Rhabdoid Tumor
2
Neoplasms, Germ Cell and Embryonal
2
Medulloblastoma
2
Lymphoma
2
Liposarcoma
2
Fallopian Tube Neoplasms
2
Diffuse Intrinsic Pontine Glioma
2
Brain Neoplasms
2
Astrocytoma
2
Thymus Neoplasms
1
Teratoma
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Sarcoma, Synovial
1
Sarcoma
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Prostatic Neoplasms
1
Pinealoma
1
Osteitis Deformans
1
Oligodendroglioma
1
Non functioning pancreatic endocrine tumor
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Interventions
Cyclophosphamide
227
Cytarabine
194
fludarabine phosphate
138
Methotrexate
132
Filgrastim
127
Busulfan
102
Etoposide
98
Peripheral Blood Stem Cell Transplantation
90
Rituximab
81
fludarabine
77
Radiotherapy
77
Vincristine
74
Daunorubicin
68
Antilymphocyte Serum
65
Cyclosporine
62
Dexamethasone
61
Tacrolimus
56
Mycophenolic Acid
52
Melphalan
52
Imatinib Mesylate
50
Granulocyte Colony-Stimulating Factor
50
Mercaptopurine
46
Whole-Body Irradiation
44
Idarubicin
43
sargramostim
42
Methylprednisolone
42
Doxorubicin
41
Flow Cytometry
40
Prednisone
39
Clofarabine
39
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Leukemia
×
ribociclib
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts